Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2020 / N 2

Ведение пациентов с COVID-19 и бронхиальной астмой: обзор литературы и клинический опыт авторов
Д.С. Фомина, С.А. Сердотецкова, М.С. Иванова, А.С. Белевский, Н.П. Княжеская, А.В. Лунцов, А.А. Чернов


References


1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DS, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. The New England Journal of Medicine 2020 Apr 30;382(18):1708-20.
2. Wang T, Zhang F, Wang X, Li X, Ling H, Lv D, Yin X, Lu Q. Predictive factors associated with glycaemic response to exenatide in Chinese patients with type 2 diabetes mellitus. Journal of Clinical Pharmacology & Therapeutics 2020 Oct;45(5):1050-7.
3. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet. Respiratory Medicine 2020 Apr;8(4):420-2.
4. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, Jiang B. Comorbidities and multi-organ injuries in the treatment of COVID-19. The Lancet 2020 Mar;395(10228):e52.
5. Zhang J, Dong X, Cao Y, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020 Jul;75(7):1730-41.
6. Huang K, Yang T, Xu J, Yang L, Zhao J, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Chen Y, Sun T, Shan G, Lin Y, Xu G, Wu S, Wang C, Wang R, Shi Z, Xu Y, Ye X, Song Y, Wang Q, Zhou Y, Li W, Ding L, Chun Wan C, Yao W, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Xiao D, Wang Z, Chen Z, Bu X, Zhang H, Zhang X, An L, Zhang S, Zhu J, Cao Z, Zhan Q, Yang Y, Liang L, Tong X, Dai H, Cao B, Wu T, Chung KF, He J, Wang C; China Pulmonary Health (CPH) Study Group. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. The Lancet 2019 Aug;394(10196):407-18.
7. Ministério da Saúde (BR) 2020. Boletim epidemiológico especial COE-COVID-19: semana epidemiológica 21. Brasília (DF). Available from: https://www.saude.gov.br/images/pdf/2020/May/29/2020-05-25---BEE17---Boletim-do-COE.pdf Accessed 2020 Oct 21.
8. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; the Northwell COVID-19 Research Consortium; Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 2020 May;323(20):2052-9.
9. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, Prill M, Chai SJ, Kirley PD, Alden NB, Kawasaki B, Yousey-Hindes K, Niccolai L, Anderson EJ, Openo KP, Weigel A, Monroe ML, Ryan P, Henderson J, Kim S, Como-Sabetti K, Lynfield R, Sosin D, Torres S, Muse A, Bennett NM, Billing L, Sutton M, West N, Schaffner W, Talbot HK, Aquino C, George A, Budd A, Brammer L, Langley G, Hall AJ, Fry A. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed Coronavirus disease 2019 – COVID-NET, 14 States, March 1–30, 2020. Morbidity and Mortality Weekly Report 2020;69:458-64.
10. Korean Society of Infectious Diseases; Korean Society of Pediatric Infectious Diseases; Korean Society of Epidemiology; Korean Society for Antimicrobial Therapy; Korean Society for Healthcare-associated Infection Control and Prevention; Korea Centers for Disease Control and Prevention. Report on the epidemiological features of coronavirus disease 2019 (COVID-10) outbreak in the Republic of Korea from January 19 to March 2, 2020. Journal of Korean Medical Science 2020 Mar;35(10):e112.
11. Antonicelli L, Tontini C, Manzotti G, Ronchi L, Vaghi A, Bini F, Scartabellati A, Menzella F, De Michele F, Musarra A, Micheletto C, Bilò MB. Severe asthma in adults does not significantly affect the outcome of COVID-19 disease: results from the Italian Severe Asthma Registry. Allergy 2020 Aug 14;10.1111/all.14558. doi: 10.1111/all.14558. Online ahead of print.
12. Bai C, Chotirmall SH, Rello J, Alba GA, Ginns LC, Krishnan JA, Rogers R, Bendstrup E, Burgel PR, Chalmers JD, Chua A, Crothers KA, Duggal A, Kim YW, Laffey JG, Luna CM, Niederman MS, Raghu G, Ramirez JA, Riera J, Roca O, Tamae-Kakazu M, Torres A, Watkins RR, Barrecheguren M, Belliato M, Chami HA, Chen R, Cortes-Puentes GA, Delacruz C, Hayes MM, Heunks LMA, Holets SR, Hough CL, Jagpal S, Jeon K, Johkoh T, Lee MM, Liebler J, McElvaney GN, Moskowitz A, Oeckler RA, Ojanguren I, O’Regan A, Pletz MW, Rhee CK, Schultz MJ, Storti E, Strange C, Thomson CC, Torriani FJ, Wang X, Wuyts W, Xu T, Yang D, Zhang Z, Wilson KC. Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). European Respiratory Review 2020 Oct;29(157):200287. doi:10.1183/16000617.0287-2020.
13. Yamaya M. Virus infection-induced bronchial asthma exacerbation. Pulmonary Medicine 2012;2012:834826.
14. Kurai D, Saraya T, Ishii H, Takizawa H. Virus-induced exacerbations in asthma and COPD. Frontiers in Microbiology 2013 Oct;4:293.
15. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, Symington P, O’Toole SO, Myint SH, Tyrrell DA. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. BMJ 1995 May 13;310(6989):1225-9.
16. Buhl R, Pfaar O, Fogelmeier C, Pletz M. PneumoLive, April 9, 2020. COVID-19: recent developments and implications on asthma, COPD and allergy. Available from: https://streamed-up.com Accessed 2020 Oct 21.
17. Schwarze J, Openshaw P, Jha A, Giacco SR, Firinu D, Tsilochristou O, Roberts G, Selby A, Akdis C, Agache I, Custovic A, Heffler E, Pinna G, Khaitov M, Nikonova A, Papadopoulos N, Akhlaq A, Nurmatov U, Renz H, Sheikh A, Skevaki C. Influenza burden, prevention, and treatment in asthma: a scoping review by the EAACI Influenza in asthma task force. Allergy 2018 Jun;73(6):1151-81.
18. Global Initiative for Asthma. Available from: www.ginasthma.org Accessed 2020 Oct 21.
19. World Health Organization. Coronavirus disease 2019 (COVID-19) situation report-52. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200312-sitrep-52-covid-19.pdf?sfvrsn=e2bfc9c0_4 Accessed 2020 Oct 21.
20. Morais-Almeida M, Aguiar R, Martin B, Ansotegui IJ, Ebisawa M, Arruda LK, Caminati M, Canonica GW, Carr T, Chupp G, Corren J, Dávila I, Park HS, Hanania NA, Rosenwasser L, Sánchez-Borges M, Virchow JC, Yáñez A, Bernstein JA, Caraballo L, Chang YS, Chikhladze M, Fiocchi A, González-Diaz SN, Tanno LK, Levin M, Ortega-Martell JA, Passalacqua G, Peden DB, Rouadi PW, Sublett JL, Wong GWK, Bleecker ER. COVID-19, asthma, and biological therapies: what we need to know. The World Allergy Organization Journal 2020 May;13(5):100126.
21. Qian GQ, Yang NB, Ding F, Ma AHY, Wang ZY, Shen YF, Shi CW, Lian X, Chu JG, Chen L, Wang ZY, Ren DW, Li GX, Chen XQ, Shen HJ, Chen XM. Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series. QJM 2020 Jul 1;113(7):474-81.
22. Chusid MJ. Eosinophils: friends or foes? The Journal of Allergy and Clinical Immunology. In Practice 2018 Sep;6(5):1439-44.
23. Zhao L, Zhang YP, Yang, X, Liu X. Eosinopenia is associated with greater severity in patients with coronavirus disease 2019. Allergy 2020 Jun 16;10.1111/all.14455. doi: 10.1111/all.14455. Online ahead of print.
24. Förster-Ruhrmann U, Szczepek AJ, Bachert C, Olze H. COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab. The Journal of Allergy and Clinical Immunology 2020 Jul;146(1):218-220.e2.
25. Lommatzsch M, Stoll P, Virchow JC. COVID-19 in a patient with severe asthma treated with omalizumab. Allergy 2020 Jun 16;10.1111/all.14456. doi: 10.1111/all.14456. Online ahead of print.
26. Cardet JC, Casale TB. New insights into the utility of omalizumab. The Journal of Allergy and Clinical Immunology 2019 Mar;143(3):923-6.
27. Gill MA, Liu AH, Calatroni A, Krouse RZ, Shao B, Schiltz A, Gern JE, Togias A, Busse WW. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. The Journal of Allergy and Clinical Immunology 2018 May;141(5):1735-43.e9.
28. Esquivel A, Busse WW, Calatroni A, Togias AG, Grindle KG, Bochkov YuA, Gruchalla RS, Kattan M, Kercsmar CM, Hershey GK, Kim H, Lebeau P, Liu AH, Szefler SJ, Teach SJ, West JB, Wildfire J, Pongracic JA, Gern JE. Effects of omali­zumab on rhinovirus infections, illnesses, and exacerbations of asthma. American Journal of Respiratory and Critical Care Medicine 2017 Oct;196(8):985-92.
29. Yalcin AD, Yalcin AN. A case of asthma with Behcet’s disease: successful treatment with omalizumab and its effects on recurrent aphthous lesions. Immunopharmacology and Immunotoxicology 2020 Aug;42(4):379-82.
30. Yalcin AD, Cilli A, Bisgin A, Strauss LG, Herth F. Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, D-dimer, CXCL8, 25-hydroxyvitamin D and IL-1beta levels. Expert Opinion on Biological Therapy 2013 Sep;13(9):1335-41.
31. Yalcin AD. A case of netherton syndrome: successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels. Immunopharmacology and Immunotoxicology 2016;38(2):162-6.
32. Yalcin AD, Celik B, Gumuslu S. D-dimer levels decreased in severe allergic asthma and chronic urticaria patients with the omalizumab treatment. Expert Opinion at Biological Therapy 2014 Mar;14(3):283-6.
33. Yalcin AD. Advances in anti-IgE therapy. BioMed Research International 2015;2015:317465.
34. Yalcin AD, Uzun R, Yalcin AN. Omalizumab treatment in bronchiectasis with allergic Asthma: long-term follow up. Oral presentation [SS-143]. At: 41st National Congress Respirology 2019 with International participation. 2019 Oct 26–29; Istanbul, Turkey. Available from: https://www.abstractagent.com/2019solunum/?plng=eng Accessed 2020 Oct 21.
35. Yalcin AD, Yalcin AN. Future perspective: biologic agents in patients with severe COVID-19. Immunopharmacology and Immunotoxicology 2020 Sep 14;1-7. doi: 10.1080/08923973.2020.1818770. Online ahead of print.
36. Baldallo C, León Román JC, Serón D, Agraz I, Solans R, Ramos N, Soler MJ. COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab. Nefrologia 2020 Jul 27;S0211-6995(20)30095-3. doi: 10.1016/j.nefro.2020.07.001. Online ahead of print.
37. Criado PR, Criado RFJ, Pincelli TP, Yoshimoto TA, Naufal GGA, Abdalla BMZ. Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab. International Journal of Dermatology 2020 Aug 17:10.1111/ijd.15134. doi: 10.1111/ijd.15134. Online ahead of print.
38. Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, Shimotai Y, Momma H, Ichinose M, Kawase T. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respiratory Investigation 2020 May;58(3):155-68.
39. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, Woodruff PG, Mauger DT, Erzurum SC, Johansson MW, Denlinger LC, Jarjour NN, Castro M, Hastie AT, Moore W, Ortega VE, Bleecker ER, Wenzel SE, Israel E, Levy BD, Seibold MA, Fahy JV. COVID-19 related genes in sputum cells in asthma: relationship to demographic features and corticosteroids. American Journal of Respiratory and Critical Care Medicine 2020 Jul;202(1):83-90.
40. Iwabuchi K, Yoshie K, Kurakami Y, Takahashi K, Kato Y, Morishima T. COVID-19. Three cases improved with inhaled ciclesonide in the early to middle stages of pneumonia. 2020. (In Japanese). Available from: http://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_casereport_200310.pdf Accessed 2020 Oct 21.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]